Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-12-9
pubmed:abstractText
SH2-containing 5'-inositol phosphatase (SHIP2) is a known regulator of insulin function. Genetic knockout of SHIP2 in mice causes mild insulin hypersensitivity and prevents high-fat-diet-induced obesity. SHIP2 also regulates actin remodeling and epidermal growth factor receptor (EGFR) turnover and supports breast cancer; and metastatic growth. To determine the clinical significance of SHIP2 expression in breast cancer and its relationship to relevant oncogenic molecules, SHIP2 expression was determined immunohistochemically in 285 primary breast cancers; 140 ductal carcinomas in situ (DCIS) and 145 invasive carcinomas. Forty-five percent of the specimens showed high SHIP2 levels in cancer cells while only 15% of adjacent normal cells expressed high SHIP2 levels (p < 0.0001). In cancer cells, the risk of SHIP2 overexpression is elevated (a) in women aged < or =50 years (relative risk, RR = 4.13; 95% confidence interval, CI, 2.5-6.9) compared to women aged >50 years (RR = 2.37; 95% CI 1.6-3.5; p = 0.0003), and (b) in invasive carcinomas (RR = 3.52; 95% CI 2.3-5.5) compared with DCIS (RR = 2.22; 95% CI 1.5-3.5; p = 0.0009). Patients with higher SHIP2 levels in invasive carcinomas had significantly reduced disease-free (p = 0.0025) and overall survival periods (p = 0.0228). In invasive carcinomas, SHIP2 correlated with estrogen receptor absence (p = 0.003) and EGFR presence (p = 0.0147). In conclusion, SHIP2 is an important biomarker for breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1423-0380
pubmed:author
pubmed:copyrightInfo
Copyright 2008 S. Karger AG, Basel.
pubmed:issnType
Electronic
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
330-41
pubmed:meshHeading
pubmed-meshheading:19065064-Adult, pubmed-meshheading:19065064-Aged, pubmed-meshheading:19065064-Aged, 80 and over, pubmed-meshheading:19065064-Blotting, Western, pubmed-meshheading:19065064-Breast Neoplasms, pubmed-meshheading:19065064-Carcinoma, Ductal, Breast, pubmed-meshheading:19065064-Carcinoma, Intraductal, Noninfiltrating, pubmed-meshheading:19065064-Case-Control Studies, pubmed-meshheading:19065064-Female, pubmed-meshheading:19065064-Humans, pubmed-meshheading:19065064-Immunoenzyme Techniques, pubmed-meshheading:19065064-Middle Aged, pubmed-meshheading:19065064-Neoplasm Invasiveness, pubmed-meshheading:19065064-PTEN Phosphohydrolase, pubmed-meshheading:19065064-Phosphoric Monoester Hydrolases, pubmed-meshheading:19065064-Prognosis, pubmed-meshheading:19065064-Survival Rate, pubmed-meshheading:19065064-Tumor Markers, Biological, pubmed-meshheading:19065064-src Homology Domains
pubmed:year
2008
pubmed:articleTitle
High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival.
pubmed:affiliation
Basic Medical Sciences and Purdue Cancer Center, Purdue University, West Lafayette, IN 47907, USA. nprasad@purdue.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't